• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喹诺酮羧酸依诺沙星的体外活性与诺氟沙星、新型β-内酰胺类、氨基糖苷类及甲氧苄啶的体外活性比较。

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

作者信息

Chin N X, Neu H C

出版信息

Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.

DOI:10.1128/AAC.24.5.754
PMID:6229216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC185938/
Abstract

Enoxacin is a new quinolone carboxylic acid compound. Its activity against 740 bacterial isolates was determined. It inhibited 90% Escherichia coli, Klebsiella sp., Aeromonas sp., Enterobacter spp., Serratia spp., Proteus mirabilis, and Morganella morganii at less than or equal to 0.8 micrograms/ml. The majority of Pseudomonas aeruginosa was inhibited by less than or equal to 3.1 micrograms/ml. Haemophilus spp. and Neisseria spp. were inhibited by less than 0.1 micrograms/ml. Although most Staphylococcus aureus were inhibited by 3.1 micrograms/ml, some streptococcal species had minimal inhibitory concentrations of 6.3 to 12.5 micrograms/ml and Bacteroides sp. had minimal inhibitory concentrations greater than or equal to 25 micrograms/ml. Activity of enoxacin and norfloxacin was similar. Enoxacin inhibited organisms resistant to cefotaxime, moxalactam, gentamicin, and piperacillin. Enoxacin was less active in urine at an acid pH than in broth, but serum did not decrease minimal inhibitory concentrations or minimal bactericidal concentrations. There was no major difference between minimal inhibitory concentrations and minimal bactericidal concentrations. Resistance frequency development was less than 10(-9) for most bacterial species.

摘要

依诺沙星是一种新型喹诺酮羧酸化合物。测定了其对740株细菌分离株的活性。它在小于或等于0.8微克/毫升时可抑制90%的大肠杆菌、克雷伯菌属、气单胞菌属、肠杆菌属、沙雷菌属、奇异变形杆菌和摩根摩根菌。大多数铜绿假单胞菌在小于或等于3.1微克/毫升时被抑制。嗜血杆菌属和奈瑟菌属在小于0.1微克/毫升时被抑制。虽然大多数金黄色葡萄球菌在3.1微克/毫升时被抑制,但一些链球菌的最低抑菌浓度为6.3至12.5微克/毫升,拟杆菌属的最低抑菌浓度大于或等于25微克/毫升。依诺沙星和诺氟沙星的活性相似。依诺沙星可抑制对头孢噻肟、莫西沙星、庆大霉素和哌拉西林耐药的菌株。依诺沙星在酸性pH的尿液中的活性低于在肉汤中的活性,但血清不会降低最低抑菌浓度或最低杀菌浓度。最低抑菌浓度和最低杀菌浓度之间没有显著差异。大多数细菌种类的耐药频率发展低于10^(-9)。

相似文献

1
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸依诺沙星的体外活性与诺氟沙星、新型β-内酰胺类、氨基糖苷类及甲氧苄啶的体外活性比较。
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.
2
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸类药物诺氟沙星的体外活性与β-内酰胺类、氨基糖苷类及甲氧苄啶的比较。
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
3
In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.培氟沙星与依诺沙星、诺氟沙星、庆大霉素及新型β-内酰胺类药物的体外活性比较。
J Antimicrob Chemother. 1985 Jan;15(1):39-44. doi: 10.1093/jac/15.1.39.
4
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.喹诺酮羧酸类药物氧氟沙星与其他喹诺酮类药物及其他抗菌药物的体外活性比较。
J Antimicrob Chemother. 1985 Nov;16(5):563-74. doi: 10.1093/jac/16.5.563.
5
Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.依诺沙星(CI-919,AT-2266)与十一种抗铜绿假单胞菌药物对氨基糖苷类敏感和耐药的铜绿假单胞菌菌株的体外活性比较
Antimicrob Agents Chemother. 1984 Sep;26(3):417-8. doi: 10.1128/AAC.26.3.417.
6
A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.环丙沙星及类似抗菌药物的实验室评估
Eur J Clin Microbiol. 1984 Aug;3(4):328-32. doi: 10.1007/BF01977488.
7
Antibacterial activity of enoxacin: comparison with aminoglycosides, beta-lactams and other antimicrobial agents.
J Antimicrob Chemother. 1986 Mar;17(3):297-302. doi: 10.1093/jac/17.3.297.
8
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.诺氟沙星、环丙沙星、依诺沙星和萘啶酸对从住院感染患者中分离出的423株革兰氏阴性杆菌和葡萄球菌的体外比较活性。
J Antimicrob Chemother. 1986 Jan;17(1):63-7. doi: 10.1093/jac/17.1.63.
9
In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
Chemioterapia. 1984 Aug;3(4):235-41.
10
In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.洛美沙星(SC - 47111;NY - 198),一种二氟喹诺酮3 - 羧酸,与其他喹诺酮类药物相比的体外活性。
Antimicrob Agents Chemother. 1988 May;32(5):656-62. doi: 10.1128/AAC.32.5.656.

引用本文的文献

1
Advances in the Synthesis and Biological Applications of Enoxacin-Based Compounds.依诺沙星类化合物的合成及生物应用进展。
Biomolecules. 2024 Nov 7;14(11):1419. doi: 10.3390/biom14111419.
2
The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives.一种知名抗生素的新面貌:依诺沙星及其衍生物的抗癌活性综述
Cancers (Basel). 2022 Jun 22;14(13):3056. doi: 10.3390/cancers14133056.
3
Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.恩诺沙星直接抑制破骨细胞生成,而不诱导细胞凋亡。
J Biol Chem. 2012 May 18;287(21):17894-17904. doi: 10.1074/jbc.M111.280511. Epub 2012 Apr 2.
4
Synthesis, characterization, antibacterial and anti-inflammatory activities of enoxacin metal complexes.合成、表征、抗菌和抗炎活性的依诺沙星金属配合物。
Bioinorg Chem Appl. 2009;2009:914105. doi: 10.1155/2009/914105. Epub 2009 Aug 2.
5
Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.依诺沙星:对其治疗泌尿生殖道感染临床疗效的重新评估。
Drugs. 1996 Jan;51(1):137-60. doi: 10.2165/00003495-199651010-00009.
6
Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.培氟沙星在脑膜炎患者脑脊液中的穿透情况。
Antimicrob Agents Chemother. 1984 Sep;26(3):289-91. doi: 10.1128/AAC.26.3.289.
7
In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.依诺沙星及其他17种抗菌剂对多重耐药革兰氏阴性菌的体外活性
Antimicrob Agents Chemother. 1984 Jul;26(1):97-100. doi: 10.1128/AAC.26.1.97.
8
Pharmacokinetics and tissue penetration of enoxacin.依诺沙星的药代动力学和组织穿透性。
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
9
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.与其他抗生素相比,WIN 49375对癌症患者分离菌株的体外活性。
Antimicrob Agents Chemother. 1984 Sep;26(3):421-3. doi: 10.1128/AAC.26.3.421.
10
Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.依诺沙星(CI-919,AT-2266)与十一种抗铜绿假单胞菌药物对氨基糖苷类敏感和耐药的铜绿假单胞菌菌株的体外活性比较
Antimicrob Agents Chemother. 1984 Sep;26(3):417-8. doi: 10.1128/AAC.26.3.417.

本文引用的文献

1
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.新型吡啶羧酸AT-2266的体外抗菌特性
Antimicrob Agents Chemother. 1983 May;23(5):641-8. doi: 10.1128/AAC.23.5.641.
2
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.新型萘啶酸类似物AM - 715的体外抗菌活性
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
3
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.口服抗假单胞菌化合物CI-919(AT-2266)的体外活性
Antimicrob Agents Chemother. 1983 May;23(5):658-63. doi: 10.1128/AAC.23.5.658.
4
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.在琼脂中对亚抑菌浓度的诺氟沙星产生耐药性增加的微生物的快速筛选。
Antimicrob Agents Chemother. 1983 Jan;23(1):188-9. doi: 10.1128/AAC.23.1.188.
5
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸类药物诺氟沙星的体外活性与β-内酰胺类、氨基糖苷类及甲氧苄啶的比较。
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
6
Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.厌氧菌药敏试验:统计学与临床考量
J Infect Dis. 1974 Dec;130(6):588-94. doi: 10.1093/infdis/130.6.588.